Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine Versus Menactra in Healthy Adolescents/Adults Aged 10-25 Years and Booster Response to MenACWY-TT Vaccine Administered at 5 Years Post-primary Vaccination

Trial Profile

Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine Versus Menactra in Healthy Adolescents/Adults Aged 10-25 Years and Booster Response to MenACWY-TT Vaccine Administered at 5 Years Post-primary Vaccination

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2014

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 13 Jun 2013 Planned end date changed from 1 Mar 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 04 Nov 2011 Planned end date changed from 1 Nov 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top